MX2023001137A - Beta-glucocerebrosidasa mutada con estabilidad mejorada. - Google Patents
Beta-glucocerebrosidasa mutada con estabilidad mejorada.Info
- Publication number
- MX2023001137A MX2023001137A MX2023001137A MX2023001137A MX2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A MX 2023001137 A MX2023001137 A MX 2023001137A
- Authority
- MX
- Mexico
- Prior art keywords
- glucocerebrosidase
- polynucleotide
- modified
- gcase
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2011813.9A GB202011813D0 (en) | 2020-07-29 | 2020-07-29 | Polypeptide |
| GBGB2100648.1A GB202100648D0 (en) | 2021-01-18 | 2021-01-18 | Polypeptide |
| GBGB2105924.1A GB202105924D0 (en) | 2021-04-26 | 2021-04-26 | Polypeptide |
| PCT/GB2021/051969 WO2022023761A2 (en) | 2020-07-29 | 2021-07-29 | Polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001137A true MX2023001137A (es) | 2023-02-22 |
Family
ID=77265101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001137A MX2023001137A (es) | 2020-07-29 | 2021-07-29 | Beta-glucocerebrosidasa mutada con estabilidad mejorada. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240261433A1 (OSRAM) |
| EP (2) | EP4118200B1 (OSRAM) |
| JP (1) | JP2023535808A (OSRAM) |
| KR (1) | KR20230042513A (OSRAM) |
| CN (1) | CN116322744A (OSRAM) |
| AU (1) | AU2021316875B2 (OSRAM) |
| BR (1) | BR112023001583A2 (OSRAM) |
| CA (1) | CA3189801A1 (OSRAM) |
| DK (1) | DK4118200T3 (OSRAM) |
| ES (1) | ES3057448T3 (OSRAM) |
| FI (1) | FI4118200T3 (OSRAM) |
| HR (1) | HRP20251591T1 (OSRAM) |
| IL (1) | IL299811A (OSRAM) |
| MX (1) | MX2023001137A (OSRAM) |
| PT (1) | PT4118200T (OSRAM) |
| WO (1) | WO2022023761A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202532096A (zh) | 2023-12-08 | 2025-08-16 | 美商戴納立製藥公司 | 經修飾之葡萄糖腦苷脂酶多肽及其使用方法 |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| CN118086341B (zh) * | 2024-04-25 | 2024-08-02 | 上海凌医生物科技有限公司 | 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框 |
| WO2026006173A1 (en) * | 2024-06-24 | 2026-01-02 | Denali Therapeutics Inc. | Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| WO2001049830A2 (en) * | 1999-12-30 | 2001-07-12 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US8454954B2 (en) | 2007-05-16 | 2013-06-04 | The Brigham And Women's Hospital, Inc. | Treatment of synucleinopathies |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| HUE030932T2 (en) * | 2010-11-08 | 2017-06-28 | Amicus Therapeutics Inc | Increased stability and increased catalytic activity, altered, recombinant, β-glucocerebrosidase proteins |
| WO2013151663A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9574184B2 (en) * | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| EP3452102B9 (en) * | 2016-04-15 | 2024-09-04 | The Trustees of The University of Pennsylvania | Gene therapy for treating hemophilia a |
| CN112553210B (zh) | 2017-10-03 | 2024-09-24 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020006633A2 (pt) | 2017-10-03 | 2020-10-06 | Prevail Therapeutics, Inc. | terapias genéticas para distúrbios lisossômicos |
| AU2019300431A1 (en) | 2018-07-13 | 2021-01-14 | Ucl Business Ltd | Glucocerebrosidase gene therapy |
| WO2020157248A1 (en) * | 2019-02-01 | 2020-08-06 | Oxyrane Uk Ltd | Glucocerebrosidase polypeptides |
-
2021
- 2021-07-29 IL IL299811A patent/IL299811A/en unknown
- 2021-07-29 US US18/017,158 patent/US20240261433A1/en active Pending
- 2021-07-29 MX MX2023001137A patent/MX2023001137A/es unknown
- 2021-07-29 FI FIEP21752123.6T patent/FI4118200T3/fi active
- 2021-07-29 DK DK21752123.6T patent/DK4118200T3/da active
- 2021-07-29 HR HRP20251591TT patent/HRP20251591T1/hr unknown
- 2021-07-29 KR KR1020237007296A patent/KR20230042513A/ko active Pending
- 2021-07-29 AU AU2021316875A patent/AU2021316875B2/en active Active
- 2021-07-29 PT PT217521236T patent/PT4118200T/pt unknown
- 2021-07-29 WO PCT/GB2021/051969 patent/WO2022023761A2/en not_active Ceased
- 2021-07-29 EP EP21752123.6A patent/EP4118200B1/en active Active
- 2021-07-29 CA CA3189801A patent/CA3189801A1/en active Pending
- 2021-07-29 EP EP25199900.9A patent/EP4643868A3/en active Pending
- 2021-07-29 CN CN202180066422.7A patent/CN116322744A/zh active Pending
- 2021-07-29 BR BR112023001583A patent/BR112023001583A2/pt unknown
- 2021-07-29 JP JP2023506111A patent/JP2023535808A/ja active Pending
- 2021-07-29 ES ES21752123T patent/ES3057448T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4643868A3 (en) | 2026-04-08 |
| EP4643868A2 (en) | 2025-11-05 |
| IL299811A (en) | 2023-03-01 |
| AU2021316875B2 (en) | 2026-04-02 |
| WO2022023761A2 (en) | 2022-02-03 |
| KR20230042513A (ko) | 2023-03-28 |
| CN116322744A (zh) | 2023-06-23 |
| EP4118200A2 (en) | 2023-01-18 |
| JP2023535808A (ja) | 2023-08-21 |
| ES3057448T3 (en) | 2026-03-02 |
| DK4118200T3 (da) | 2025-12-08 |
| WO2022023761A3 (en) | 2022-03-10 |
| HRP20251591T1 (hr) | 2026-01-30 |
| AU2021316875A1 (en) | 2023-02-23 |
| PT4118200T (pt) | 2026-01-08 |
| CA3189801A1 (en) | 2022-02-03 |
| FI4118200T3 (fi) | 2025-12-12 |
| BR112023001583A2 (pt) | 2023-02-14 |
| US20240261433A1 (en) | 2024-08-08 |
| EP4118200B1 (en) | 2025-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4643868A3 (en) | Mutated beta-glucocerebrosidase with improved stability | |
| CO2021008538A2 (es) | Composiciones para la reducción de la expresión transgénica específica de drg | |
| AR112057A1 (es) | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b | |
| CO2018005215A2 (es) | Construcciones específicas del hígado para expresión del factor viii | |
| CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| PE20231949A1 (es) | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| AR095598A1 (es) | Composiciones y métodos para construcciones quiméricas del virus del dengue en vacunas | |
| CO6290791A2 (es) | Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws | |
| AR090470A1 (es) | Vacuna contra el virus sincicial respiratorio (rsv) | |
| MX2021009305A (es) | Polinucleotidos. | |
| RU2017142006A (ru) | Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| MX2021000328A (es) | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. | |
| CL2020001428A1 (es) | Terapia genética para la mucopolisacaridosis iiib. | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| AR115152A1 (es) | Elementos reguladores de plantas y métodos de uso de los mismos | |
| CO6290694A2 (es) | Paramyxovirus eficaz como antitumoral | |
| CO2017005830A2 (es) | Composiciones de vacuna para el virus del dengue | |
| AR118005A1 (es) | Administración del virus adenoasociado de polinucleótido de cln3 | |
| ECSP23095204A (es) | Composiciones y métodos para mejorar la función visual | |
| MX2022000038A (es) | Virus del dengue atenuados. | |
| AR126396A1 (es) | VARIANTES DESOPTIMIZADAS DE SARS-CoV-2 Y MÉTODOS Y USOS DE LAS MISMAS |